Second-Generation AUTACs for Targeted Autophagic Degradation

  • J Med Chem. 2023 Sep 14;66(17):12342-12372. doi: 10.1021/acs.jmedchem.3c00861.
Daiki Takahashi  1 Taiichi Ora  2 Shigekazu Sasaki  2 Naoki Ishii  2 Toshio Tanaka  2 Takumi Matsuda  1 Mutsuki Ikeda  1 Jun Moriyama  1 Nobuo Cho  2 Hiroshi Nara  2 Hironobu Maezaki  2 Masahiro Kamaura  2 Kenichiro Shimokawa  2 Hirokazu Arimoto  1
Affiliations
  • 1. Graduate School of Life Sciences, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
  • 2. Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Abstract

Targeted protein degradation via the ubiquitin-proteasome system has emerged as one of the most promising drug discovery modalities. Autophagy, another intracellular degradation system, can target a wide range of nonproteinous substrates as well as proteins, but its application to targeted degradation is still in its infancy. Our previous work revealed a relationship between guanine modification of cysteine residues on intracellular proteins and selective Autophagy, resulting in the first autophagy-based degraders, autophagy-targeted chimeras (AUTACs). Based on the research background, all the reported AUTACs compounds contain cysteine as a substructure. Here, we examine the importance of this substructure by conducting SAR studies and report significant improvements in the degrader's activity by replacing cysteine with Other moieties. Several derivatives showed sub-μM range degrading activity, demonstrating the increased practical value of AUTACs.

Products